Logo image of STOK

STOKE THERAPEUTICS INC (STOK) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:STOK - US86150R1077 - Common Stock

30.05 USD
+0.55 (+1.86%)
Last: 1/22/2026, 8:04:13 PM
30.05 USD
0 (0%)
After Hours: 1/22/2026, 8:04:13 PM
Fundamental Rating

5

Taking everything into account, STOK scores 5 out of 10 in our fundamental rating. STOK was compared to 525 industry peers in the Biotechnology industry. STOK has an excellent financial health rating, but there are some minor concerns on its profitability. STOK has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • STOK had positive earnings in the past year.
  • STOK had a positive operating cash flow in the past year.
  • STOK had negative earnings in each of the past 5 years.
  • STOK had a negative operating cash flow in each of the past 5 years.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • With an excellent Return On Assets value of 11.39%, STOK belongs to the best of the industry, outperforming 94.10% of the companies in the same industry.
  • STOK's Return On Equity of 13.32% is amongst the best of the industry. STOK outperforms 94.10% of its industry peers.
  • With an excellent Return On Invested Capital value of 6.66%, STOK belongs to the best of the industry, outperforming 92.95% of the companies in the same industry.
Industry RankSector Rank
ROA 11.39%
ROE 13.32%
ROIC 6.66%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • The Profit Margin of STOK (19.96%) is better than 93.52% of its industry peers.
  • Looking at the Operating Margin, with a value of 13.06%, STOK belongs to the top of the industry, outperforming 92.57% of the companies in the same industry.
Industry RankSector Rank
OM 13.06%
PM (TTM) 19.96%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), STOK is destroying value.
  • Compared to 1 year ago, STOK has more shares outstanding
  • The number of shares outstanding for STOK has been increased compared to 5 years ago.
  • STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • STOK has an Altman-Z score of 19.62. This indicates that STOK is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 19.62, STOK belongs to the top of the industry, outperforming 88.76% of the companies in the same industry.
  • STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 19.62
ROIC/WACC0.75
WACC8.9%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • STOK has a Current Ratio of 6.53. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
  • STOK has a Current ratio of 6.53. This is in the better half of the industry: STOK outperforms 66.67% of its industry peers.
  • STOK has a Quick Ratio of 6.53. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
  • STOK has a better Quick ratio (6.53) than 67.43% of its industry peers.
Industry RankSector Rank
Current Ratio 6.53
Quick Ratio 6.53
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 135.71% over the past year.
  • STOK shows a strong growth in Revenue. In the last year, the Revenue has grown by 1128.17%.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.3%
Revenue 1Y (TTM)1128.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%117.25%

3.2 Future

  • Based on estimates for the next years, STOK will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.08% on average per year.
  • The Revenue is expected to grow by 75.70% on average over the next years. This is a very strong growth
EPS Next Y110.25%
EPS Next 2Y-37.88%
EPS Next 3Y-14.81%
EPS Next 5Y17.08%
Revenue Next Year941.71%
Revenue Next 2Y37.42%
Revenue Next 3Y52.87%
Revenue Next 5Y75.7%

3.3 Evolution

STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 40.07 indicates a quite expensive valuation of STOK.
  • Compared to the rest of the industry, the Price/Earnings ratio of STOK indicates a rather cheap valuation: STOK is cheaper than 91.81% of the companies listed in the same industry.
  • STOK is valuated rather expensively when we compare the Price/Earnings ratio to 27.32, which is the current average of the S&P500 Index.
  • The Forward Price/Earnings Ratio is negative for STOK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 40.07
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • STOK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. STOK is cheaper than 91.43% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, STOK is valued cheaper than 93.90% of the companies in the same industry.
Industry RankSector Rank
P/FCF 32.66
EV/EBITDA 45.34
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • STOK's earnings are expected to decrease with -14.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y-37.88%
EPS Next 3Y-14.81%

0

5. Dividend

5.1 Amount

  • No dividends for STOK!.
Industry RankSector Rank
Dividend Yield 0%

STOKE THERAPEUTICS INC / STOK FAQ

What is the fundamental rating for STOK stock?

ChartMill assigns a fundamental rating of 5 / 10 to STOK.


Can you provide the valuation status for STOKE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to STOKE THERAPEUTICS INC (STOK). This can be considered as Fairly Valued.


Can you provide the profitability details for STOKE THERAPEUTICS INC?

STOKE THERAPEUTICS INC (STOK) has a profitability rating of 4 / 10.


What is the expected EPS growth for STOKE THERAPEUTICS INC (STOK) stock?

The Earnings per Share (EPS) of STOKE THERAPEUTICS INC (STOK) is expected to grow by 110.25% in the next year.